Announced details
Treatment of Epstein-Barr virus-associated gastric cancer (EBVaGC)
The company will present a poster at the ASCO Annual Meeting on preclinical data for the antiviral drug it is developing.
Established in 1964, ASCO is an international society in the fields of cancer treatment and research, with more than 50,000 members from over 150 countries.
Abstract No. 4028
Chicago, Illinois, United States (venue for ASCO Annual Meeting 2026)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
American Society of Clinical Oncology (ASCO)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Brincidofovir (brincidofovir, BCV) |
| Counterparty | American Society of Clinical Oncology (ASCO) |
| Counterparty overview | Established in 1964, ASCO is an international society in the fields of cancer treatment and research, with more than 50,000 members from over 150 countries. |
| Relationship with the Company | The company will present a poster at the ASCO Annual Meeting on preclinical data for the antiviral drug it is developing. |
| Launch date | 29 May to 2 June 2026 (presentation scheduled) |
| Applicable area | Treatment of Epstein-Barr virus-associated gastric cancer (EBVaGC) |
| Registration number and expiry date | Abstract No. 4028 |
| Location | Chicago, Illinois, United States (venue for ASCO Annual Meeting 2026) |
| Source | American Society of Clinical Oncology (ASCO) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No specific anticancer therapy has been established for Epstein-Barr virus-associated gastric cancer, and the data indicate that BCV may represent a new treatment option.